» Articles » PMID: 34380878

Promise of Metformin for Preventing Age-related Cognitive Dysfunction

Overview
Date 2021 Aug 12
PMID 34380878
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The expanded lifespan of people, while a positive advance, has also amplified the prevalence of age-related disorders, which include mild cognitive impairment, dementia, and Alzheimer's disease. Therefore, competent therapies that could improve the healthspan of people have great significance. Some of the dietary and pharmacological approaches that augment the lifespan could also preserve improved cognitive function in old age. Metformin, a drug widely used for treating diabetes, is one such candidate that could alleviate age-related cognitive dysfunction. However, the possible use of metformin to alleviate age-related cognitive dysfunction has met with conflicting results in human and animal studies. While most clinical studies have suggested the promise of metformin to maintain better cognitive function and reduce the risk for developing dementia and Alzheimer's disease in aged diabetic people, its efficacy in the nondiabetic population is still unclear. Moreover, a previous animal model study implied that metformin could adversely affect cognitive function in the aged. However, a recent animal study using multiple behavioral tests has reported that metformin treatment in late middle age improved cognitive function in old age. The study also revealed that cognition-enhancing effects of metformin in aged animals were associated with the activation of the energy regulator adenosine monophosphate-activated protein kinase, diminished neuroinflammation, inhibition of the mammalian target of rapamycin signaling, and augmented autophagy in the hippocampus. The proficiency of metformin to facilitate these favorable modifications in the aged hippocampus likely underlies its positive effect on cognitive function. Nonetheless, additional studies probing the outcomes of different doses and durations of metformin treatment at specific windows in the middle and old age across sex in nondiabetic and non-obese prototypes are required to substantiate the promise of metformin to maintain better cognitive function in old age.

Citing Articles

Premature cognitive decline in a mouse model of tuberous sclerosis.

Krummeich J, Nardi L, Caliendo C, Aschauer D, Engelhardt V, Arlt A Aging Cell. 2024; 23(12):e14318.

PMID: 39192595 PMC: 11634721. DOI: 10.1111/acel.14318.


TET2 deficiency promotes anxiety and depression-like behaviors by activating NLRP3/IL-1β pathway in microglia of allergic rhinitis mice.

Gao Z, Lv H, Wang Y, Xie Y, Guan M, Xu Y Mol Med. 2023; 29(1):160.

PMID: 38012545 PMC: 10680276. DOI: 10.1186/s10020-023-00757-9.


Heterogeneous treatment effects of metformin on risk of dementia in patients with type 2 diabetes: A longitudinal observational study.

Tang H, Guo J, Shaaban C, Feng Z, Wu Y, Magoc T Alzheimers Dement. 2023; 20(2):975-985.

PMID: 37830443 PMC: 10917005. DOI: 10.1002/alz.13480.


Metformin Prevents NDEA-Induced Memory Impairments Associated with Attenuating Beta-Amyloid, Tumor Necrosis Factor-Alpha, and Interleukin-6 Levels in the Hippocampus of Rats.

Ponce-Lopez T, Gonzalez Alvarez Tostado J, Dias F, Montiel Maltez K Biomolecules. 2023; 13(9).

PMID: 37759689 PMC: 10526195. DOI: 10.3390/biom13091289.


The potential effect of metformin on cognitive and other symptom dimensions in patients with schizophrenia and antipsychotic-induced weight gain: a systematic review, meta-analysis, and meta-regression.

Battini V, Cirnigliaro G, Leuzzi R, Rissotto E, Mosini G, Benatti B Front Psychiatry. 2023; 14:1215807.

PMID: 37502816 PMC: 10370497. DOI: 10.3389/fpsyt.2023.1215807.


References
1.
Stern Y . Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol. 2012; 11(11):1006-12. PMC: 3507991. DOI: 10.1016/S1474-4422(12)70191-6. View

2.
Galluzzi L, Baehrecke E, Ballabio A, Boya P, Bravo-San Pedro J, Cecconi F . Molecular definitions of autophagy and related processes. EMBO J. 2017; 36(13):1811-1836. PMC: 5494474. DOI: 10.15252/embj.201796697. View

3.
Bockaert J, Marin P . mTOR in Brain Physiology and Pathologies. Physiol Rev. 2015; 95(4):1157-87. DOI: 10.1152/physrev.00038.2014. View

4.
Vingtdeux V, Giliberto L, Zhao H, Chandakkar P, Wu Q, Simon J . AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem. 2010; 285(12):9100-13. PMC: 2838330. DOI: 10.1074/jbc.M109.060061. View

5.
Samaras K, Makkar S, Crawford J, Kochan N, Wen W, Draper B . Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study. Diabetes Care. 2020; 43(11):2691-2701. DOI: 10.2337/dc20-0892. View